Arcturus Therapeutics Holdings' (NASDAQ:ARCT) investors will be pleased with their impressive 284% return over the last five years [Yahoo! Finance]
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024 [Yahoo! Finance]
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.
Arcturus Therapeutics Holdings Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag [Yahoo! Finance]